Hamada, Tsuyoshi
Yuan, Chen
Yurgelun, Matthew B.
Perez, Kimberly
Khalaf, Natalia
Morales-Oyarvide, Vicente
Babic, Ana
Nowak, Jonathan A.
Rubinson, Douglas A.
Giannakis, Marios
Ng, Kimmie
Kraft, Peter
Stampfer, Meir J.
Giovannucci, Edward L.
Fuchs, Charles S.
Ogino, Shuji
Wolpin, Brian M.
Article History
Received: 13 November 2018
Revised: 25 February 2019
Accepted: 27 February 2019
First Online: 14 March 2019
Competing interests
: C.S.F. declares consulting for Agios Inc., Bain Capital L.P., Bayer A.G., Celgene Inc., Dicerna Inc., Eli Lilly, Entrinsic Health Solutions Inc., Five Prime Therapeutics Inc., Genentech Inc., Gilead Sciences Inc., KEW Inc., Merck Inc., Merrimack Pharmaceuticals Inc., Pfizer Inc., Sanofi Inc., Taiho Ltd., and Unum Therapeutics Inc. He also serves as a director for CytomX Therapeutics Inc. and owns unexercised stock options for CytomX Therapeutics Inc. and Entrinsic Health Solutions Inc. B.M.W. declares research funding from Celgene Inc., and consulting for BioLineRx Ltd., G1 Therapeutics Inc., and GRAIL Inc. The remaining authors declare no competing interests.
: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
: Informed consent was obtained from all participants at study enrolment, and the HPFS was approved by the institutional review board at Harvard T.H. Chan School of Public Health (Boston, MA, USA). The study was conducted in accordance with the Declaration of Helsinki.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).